Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

832
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
832
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

684
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
684

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Speech-in-noise recognition during hearing protector use: Human performance and acoustic prediction.

Hearing research·2026
Same author

Pelvic venous disorders and orthostatic intolerance: A systematic review of diagnostic associations and treatment outcomes.

Autonomic neuroscience : basic & clinical·2026
Same author

Intravascular Ultrasound in Chronic Limb-Threatening Ischemia Endovascular Revascularization: A Multidisciplinary Survey of Clinical Practices and Operator Perceptions.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Percutaneous management of post-thrombotic syndrome: Early experience with a novel thrombectomy catheter designed to address chronic venous occlusions.

Journal of vascular surgery cases and innovative techniques·2026
Same author

Eye on the Eclipse: Demographic Trends in Solar Retinopathy From 2012 to 2024.

Journal of vitreoretinal diseases·2026
Same author

Reconciliation or reputation: critical analysis of commercial sector commitments and framing in reconciliation action plans.

Health promotion international·2026

Related Experiment Video

Updated: Apr 21, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K

Dimethyl fumarate for treating relapsing multiple sclerosis.

William Sheremata1, Andrew D Brown, Kottil W Rammohan

  • 1University of Miami, Miller School of Medicine, Department of Neurology , 1120 NW 14th Street, Miami, FL 33136 , USA wsherema@med.miami.edu.

Expert Opinion on Drug Safety
|November 11, 2014
PubMed
Summary

Dimethyl fumarate (DMF) is a safe and well-tolerated oral medication for multiple sclerosis (MS). While flushing and gastrointestinal issues are common, serious adverse events like malignancies and progressive multifocal encephalopathy (PML) are rare.

Keywords:
dimethyl fumaratefumaratelymphopeniamonoethyl fumaratemultiple sclerosisneuroprotectionnuclear factor (erythroid-derived-2)-like 2progressive multifocal encephalopathy

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.5K

Related Experiment Videos

Last Updated: Apr 21, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.5K

Area of Science:

  • Neuroimmunology
  • Dermatology
  • Pharmacology

Background:

  • Dimethyl fumarate (DMF) is approved for multiple sclerosis (MS) treatment.
  • DMF's safety profile is supported by extensive use of fumaric acid esters for psoriasis.

Purpose of the Study:

  • To review pivotal trials for DMF in MS.
  • To examine the safety of DMF based on long-term use in psoriasis treatment.

Main Methods:

  • Review of clinical trial data for DMF in MS.
  • Analysis of pharmacological literature on fumaric acid esters for psoriasis.
  • Evaluation of reported adverse events.

Main Results:

  • DMF is generally safe and well-tolerated for MS.
  • Common side effects include mild, self-limiting flushing and gastrointestinal issues.
  • No increased malignancy risk observed; PML is rare, with no cases in the first year of DMF MS treatment.

Conclusions:

  • DMF demonstrates a favorable safety profile for MS treatment.
  • Long-term data from psoriasis treatment support DMF's safety.
  • While rare, PML risk necessitates ongoing monitoring.